Prapela has developed a noninvasive stimulation therapy aimed at improving the health of newborns, particularly those facing serious medical conditions such as opioid withdrawal and apnea of prematurity. The technology utilizes stochastic stimulation, which involves gentle, random movements that mimic natural physiological processes to enhance breathing patterns and oxygenation in infants. This approach is designed to be safe and effective, as it operates below the threshold that would disturb an infant's sleep cycle, thereby promoting a more stable and healthy breathing rhythm without the need for pharmacological interventions.

The foundation of Prapela's technology is rooted in extensive clinical research and collaboration with leading medical institutions, including Harvard's Wyss Institute and Massachusetts General Hospital. Over the years, studies have demonstrated the efficacy of this stimulation in improving outcomes for newborns, such as reducing apneic events and enhancing oxygen levels. Prapela's mission is to provide affordable solutions that can significantly improve the quality of life for newborns and their families, with ongoing research aimed at securing regulatory clearance for their innovative devices.

United States

Prapela is a breakthrough noninvasive stimulation therapy that naturally improves breathing and oxygenation in newborns.  Based on a field of science called Stochastic Resonance, our precise and gentle stimulation improves breathing rhythm and lung function in newborns.  Since 2017, we've received over $8M in awards and grants funding the clinical evaluation of our therapy to improve the treatment of opioid-exposed newborns and preterm infants with apnea of prematurity.  Next, we aim to improve the treatment of preterm intermittent hypoxemia and bronchopulmonary dysplasia. For more information, visit prapela.com

Prapela

Company Details